|1.||Bokemeyer, C: 2 articles (06/2013 - 06/2006)|
|2.||Schleucher, Norbert: 2 articles (06/2013 - 01/2004)|
|3.||Kollmannsberger, C: 2 articles (06/2013 - 06/2006)|
|4.||Vanhoefer, Udo: 2 articles (06/2013 - 01/2004)|
|5.||Trarbach, Tanja: 2 articles (06/2013 - 01/2004)|
|6.||Schiller, Joan H: 2 articles (12/2010 - 02/2008)|
|7.||Kurek, Raffael: 2 articles (12/2010 - 03/2009)|
|8.||Socinski, Mark A: 2 articles (12/2010 - 08/2007)|
|9.||Rao, S: 2 articles (11/2010 - 09/2008)|
|10.||Kurek, R: 2 articles (11/2010 - 09/2008)|
04/01/2008 - "In this issue of Cancer Cell, Schmiedel et al. report structural and functional studies of the anti-EGFR monoclonal antibody Matuzumab. "
03/11/2008 - "Population pharmacokinetic data analysis of three phase I studies of matuzumab, a humanised anti-EGFR monoclonal antibody in clinical cancer development."
03/01/2007 - "The primary objective of this study was to determine the rate of response to matuzumab in patients with recurrent, EGFR-positive ovarian, or primary peritoneal cancer. "
06/01/2013 - "Matuzumab, in combination with PLF, demonstrated an acceptable safety profile with modest anti-tumor activity."
01/01/2011 - "Matuzumab combined with chemoradiation did not induce cytotoxic effects on gynecological cancer cell lines in vitro, most likely due to impaired EGFR degradation. "
03/10/2005 - "Intraperitoneal injection of EMD72000 inhibits orthotopic human pancreatic carcinoma growth in rats. "
02/01/2001 - "When treated with EMD 55900 and EMD 72000 carcinomas with an EGFR concentration of > or = 70 fmol/mg protein showed significant reduction in tumor size compared with untreated controls. "
10/01/2007 - "In a pre-clinical study, we demonstrated the therapeutic effect of the combination of two humanized Ab used in clinic, trastuzumab (Ab anti-HER2) and matuzumab (Ab anti-EGFR) in vivo in different carcinoma types. "
03/10/2005 - "Magnetic resonance imaging in an orthotopic rat model: blockade of epidermal growth factor receptor with EMD72000 inhibits human pancreatic carcinoma growth."
05/01/2003 - "Xenotransplanted carcinomas with different EGFR levels were treated with monoclonal antibodies against the EGFR (EMD 72000 and EMD 55900), cisplatinum and a combination of both. "
05/08/2006 - "Three groups of chemotherapy-naive advanced pancreatic adenocarcinoma patients (n=17) received escalating doses of matuzumab (400 mg weekly, 800 mg biweekly, or 800 mg weekly) and gemcitabine (1000 mg m-2 weekly in weeks 1-3 of each 4-week cycle). "
06/01/2013 - "Phase I study of matuzumab in combination with 5-fluorouracil, leucovorin and cisplatin (PLF) in patients with advanced gastric and esophagogastric adenocarcinomas."
02/01/2001 - "To investigate the in vivo effects of monoclonal antibodies, we treated tumors derived from cell lines (A431 and Detroit 562) as well as spontaneously occurring squamous cell carci nomas and adenocarcinomas (transplanted on NMRI-nu/nu mice) gener ally with EMD 55900 (40 microg/g mouse) and its humanized version EMD 72000 (40 microg/g mouse). "
06/01/2013 - "To evaluate the safety and tolerability of two different weekly doses of the fully humanized epidermal growth factor receptor (EGFR)-targeting monoclonal antibody matuzumab combined with high-dose 5-fluorouracil, leucovorin and cisplatin (PLF) in the first-line treatment of patients with EGFR-positive advanced gastric and esophagogastric adenocarcinomas. "
|4.||Stomach Neoplasms (Stomach Cancer)
|5.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
06/01/2013 - "This phase I study investigated the tolerability, safety and pharmacokinetics (PK) of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer (NSCLC). "
06/01/2013 - "A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer."
12/01/2010 - "Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer."
03/01/2009 - "Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer."
12/24/2008 - "Matuzumab enhanced the antitumor effect of cisplatin in nude mice harboring human non-small cell lung cancer xenografts. "
|2.||Epidermal Growth Factor Receptor (EGF Receptor)
|6.||Leucovorin (Folinic Acid)
|7.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)